Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 51 min ago
Peer-reviewedCC BYCardiovascular Research

Dual inhibition of SGLT 1 and 2 by sotagliflozin alleviates intracellular sodium overload and improves cardiometabolic remodelling in uraemic cardiomyopathy

11 more authors

Abstract

AIMS: Chronic kidney disease (CKD) is associated with uraemic cardiomyopathy characterized by early metabolic dysfunction. Elevated myocardial intracellular sodium (Naᵢ) has emerged as a driver of cardiometabolic remodelling, however, its role in CKD and therapeutic modulation remains unclear. We investigated whether dual sodium-glucose cotransporter (SGLT)1/2 inhibition with sotagliflozin (SOTA) targets Naᵢ and improves cardiac metabolism in CKD. METHODS AND RESULTS: CKD was induced in male Wistar rats by 5/6 nephrectomy and assessed after 4 weeks. Cardiac phenotype was evaluated using in vivo echocardiography and ex vivo Langendorff perfusion combined with 23Na and 31P NMR spectroscopy. CKD hearts exhibited preserved systolic but impaired diastolic function and a marked elevation in myocardial Naᵢ, identifying Naᵢ overload as an early feature of uraemic cardiomyopathy. Cardiac metabolomic profiling and flux modelling demonstrated widespread suppression of central carbon metabolism, redox imbalance despite preserved PCr/ATP. In silico electrophysiological simulations predicted Naᵢ-driven Ca2+ dysregulation consistent with in vivo diastolic dysfunction. Chronic SOTA treatment (3 weeks, in vivo) normalized myocardial Naᵢ and partially reversed metabolic remodelling. Acute SOTA exposure (20 min, Langendorff-perfusion) similarly reduced Naᵢ in CKD hearts but not in controls, indicating a direct, disease-selective myocardial effect. Naᵢ normalization was accompanied by improved redox state and restoration of mitochondrial metabolic flux, without changes in expression of canonical Na + -handling proteins. CONCLUSION: Myocardial Naᵢ overload emerges as an early and potentially modifiable feature of uraemic cardiomyopathy. Dual SGLT1/2 inhibition with SOTA directly lowers Naᵢ and improves cardiac metabolic homeostasis, supporting Naᵢ as a mechanistically relevant and potentially targetable pathway in CKD-related cardiac remodelling.

Related

  1. Mechanisms of intracellular pH gating and local anesthetic inhibition of the two-pore domain K⁺ channel TASK-2.
    Trevor Docter, Ben Sorum, Baobin Li +4
    Proceedings of the National Academy of Sciences of the United States of AmericaPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMC
  2. Hypoxia drives asymmetric envelope remodelling to promote membrane adaptation and antibiotic tolerance in mycobacteria
    L. Mathew, M. Aguilar, T.-H. Lee +1
    bioRxivPreprintAll rights reservedFull textBiophysicsbioRxiv
  3. Direct measurement of PET hydrolase interfacial kinetics reveals catalysis-independent surface remodelling
    K. J. Petz, A. Boudigou, L. E. Dickson +2
    bioRxivPreprintAll rights reservedFull textBiophysicsbioRxiv
  4. Senescent Cell‐Derived Extracellular Vesicles in Therapy‐Induced Senescence: Immune Remodelling and Emerging Links to Mitochondrial Stress in Cancer
    Yongrui Qian, Zirui Weng, Na Li +2
    Journal of extracellular biologyPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMC
  5. Larval diet drives remodelling of the peritrophic matrix in the Australian sheep blowfly and influences vaccine efficacy
    Edward D. Kerr, Susan J. Briscoe, Jody McNally +4
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textMolecular biology & gene regulationCrossref
BibTeX
@article{young2026dual,
  title = {{Dual inhibition of SGLT 1 and 2 by sotagliflozin alleviates intracellular sodium overload and improves cardiometabolic remodelling in uraemic cardiomyopathy}},
  author = {Megan Young and Anja Karlstaedt and Sanushi Dambure and Jack Miller and Tong Guo and Xin Zhou and Zenouska Ramchunder and Jair Gonzalez Marques Junior and Muriel Nobles and Andrew Tinker and Kyuongmin Kim and Amanda Purcell and Sarah Glastras and Fenn Cullen and Thomas Eykyn and Alex von Kriegsheim and Blanca Rodriguez and Michelangelo Campanella and Michael Shattock and Nay Aung and Claudia Cabrera and Magdi Yaqoob and Dunja Aksentijevic},
  journal = {Cardiovascular Research},
  year = {2026},
  month = sep,
  doi = {10.1093/cvr/cvag167},
  url = {https://hal.science/hal-05863791v1},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Dual inhibition of SGLT 1 and 2 by sotagliflozin alleviates intracellular sodium overload and improves cardiometabolic remodelling in uraemic cardiomyopathy
AU  - Megan Young
AU  - Anja Karlstaedt
AU  - Sanushi Dambure
AU  - Jack Miller
AU  - Tong Guo
AU  - Xin Zhou
AU  - Zenouska Ramchunder
AU  - Jair Gonzalez Marques Junior
AU  - Muriel Nobles
AU  - Andrew Tinker
AU  - Kyuongmin Kim
AU  - Amanda Purcell
AU  - Sarah Glastras
AU  - Fenn Cullen
AU  - Thomas Eykyn
AU  - Alex von Kriegsheim
AU  - Blanca Rodriguez
AU  - Michelangelo Campanella
AU  - Michael Shattock
AU  - Nay Aung
AU  - Claudia Cabrera
AU  - Magdi Yaqoob
AU  - Dunja Aksentijevic
PY  - 2026
DA  - 2026/09/10
JO  - Cardiovascular Research
DO  - 10.1093/cvr/cvag167
UR  - https://hal.science/hal-05863791v1
AB  - AIMS: Chronic kidney disease (CKD) is associated with uraemic cardiomyopathy characterized by early metabolic dysfunction. Elevated myocardial intracellular sodium (Naᵢ) has emerged as a driver of cardiometabolic remodelling, however, its role in CKD and therapeutic modulation remains unclear. We investigated whether dual sodium-glucose cotransporter (SGLT)1/2 inhibition with sotagliflozin (SOTA) targets Naᵢ and improves cardiac metabolism in CKD. METHODS AND RESULTS: CKD was induced in male Wistar rats by 5/6 nephrectomy and assessed after 4 weeks. Cardiac phenotype was evaluated using in vivo echocardiography and ex vivo Langendorff perfusion combined with 23Na and 31P NMR spectroscopy. CKD hearts exhibited preserved systolic but impaired diastolic function and a marked elevation in myocardial Naᵢ, identifying Naᵢ overload as an early feature of uraemic cardiomyopathy. Cardiac metabolomic profiling and flux modelling demonstrated widespread suppression of central carbon metabolism, redox imbalance despite preserved PCr/ATP. In silico electrophysiological simulations predicted Naᵢ-driven Ca2+ dysregulation consistent with in vivo diastolic dysfunction. Chronic SOTA treatment (3 weeks, in vivo) normalized myocardial Naᵢ and partially reversed metabolic remodelling. Acute SOTA exposure (20 min, Langendorff-perfusion) similarly reduced Naᵢ in CKD hearts but not in controls, indicating a direct, disease-selective myocardial effect. Naᵢ normalization was accompanied by improved redox state and restoration of mitochondrial metabolic flux, without changes in expression of canonical Na + -handling proteins. CONCLUSION: Myocardial Naᵢ overload emerges as an early and potentially modifiable feature of uraemic cardiomyopathy. Dual SGLT1/2 inhibition with SOTA directly lowers Naᵢ and improves cardiac metabolic homeostasis, supporting Naᵢ as a mechanistically relevant and potentially targetable pathway in CKD-related cardiac remodelling.
SN  - 0008-6363
ER  -